Cardiothoracic & vascular anesthesia
Recombinant Factor VIIa Versus Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis
Authors' conclusion
PCC has been shown to have a beneficial effect on reducing chest tube output and incidence of thromboembolic disease, with no increase in AKI compared with rFVIIa.
Study context
- Population
- Adults undergoing cardiac surgery
- Participants
- 962 adults · 7 retrospective observational studies
- Comparison
- Prothrombin complex concentrate (PCC) vs recombinant factor VIIa
- Outcome
- Total chest tube output
Methodological details5 studies at moderate and 2 at serious risk of bias
- 5 studies at moderate and 2 at serious risk of bias
Pooled result
As reported in the abstract
Significant reduction in total chest tube output
−301.01 mL
MD; 95% CI −550.54 to −51.48
Further pooled results
| Outcome | MD (95% CI) | |
|---|---|---|
| Cryoprecipitate transfusion | −3.93 (−7.64 to −0.21) | |
| −10−505Difference (linear scale) |
Mortality
- No significant difference between groups
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| Total thromboembolic disease | 0.55 (0.34–0.89) | |
| DVT | 0.28 (0.15–0.52) | |
| 0.10.31310Odds ratio (log scale) |
Acute kidney injury (AKI)
- No significant difference between groups
Original publication
Recombinant Factor VIIa Versus Prothrombin Complex Concentrate in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis. J Cardiothorac Vasc Anesth. Published 22 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →